Jyong Biotech completes patient enrollment in Phase II trial of MCS-8

Jyong Biotech (MENS) announced that it has completed patient enrollment in its Phase II clinical trial of MCS-8, an investigational drug candidate for prostate cancer prevention, PCP, with more than 700 high-risk subject who have enrolled into this clinical trial since its commencement. “We are pleased to have reached this key milestone in the MCS-8 development program,” said Fu-Feng Kuo, Chairwoman and CEO of Jyong Biotech. “We have enrolled over 700 participants in this clinical trial, and despite the challenging times of the COVID-19 pandemic, we have successfully achieved this milestone and the progress has been ahead of our expectations. This truly reflects the team’s professionalism, patience, dedication, and commitment.”